PID
MCID: PLV003
MIFTS: 54

Pelvic Inflammatory Disease (PID)

Categories: Nephrological diseases, Reproductive diseases

Aliases & Classifications for Pelvic Inflammatory Disease

MalaCards integrated aliases for Pelvic Inflammatory Disease:

Name: Pelvic Inflammatory Disease 12 75 55 43 3 44 15 17 72
Pid 12 3

Classifications:



External Ids:

Disease Ontology 12 DOID:1003
MeSH 44 D000292
NCIt 50 C3889
SNOMED-CT 68 37518008
ICD10 33 N70-N77 N73.9
UMLS 72 C0242172

Summaries for Pelvic Inflammatory Disease

MedlinePlus : 43 Pelvic inflammatory disease (PID) is an infection and inflammation of the uterus, ovaries, and other female reproductive organs. It causes scarring in these organs. This can lead to infertility, ectopic pregnancy, pelvic pain, abscesses, and other serious problems. PID is the most common preventable cause of infertility in the United States. Gonorrhea and chlamydia, two sexually transmitted diseases, are the most common causes of PID. Other bacteria can also cause it. You are at greater risk if you Are sexually active and younger than 25 Have more than one sex partner Douche Some women have no symptoms. Others have pain in the lower abdomen, fever, smelly vaginal discharge, irregular bleeding, and pain during intercourse or urination. Doctors diagnose PID with a physical exam, lab tests, and imaging tests. Antibiotics can cure PID. Early treatment is important. Waiting too long increases the risk of infertility.

MalaCards based summary : Pelvic Inflammatory Disease, also known as pid, is related to salpingitis and peritonitis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Pelvic Inflammatory Disease is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Moxifloxacin and Norgestimate have been mentioned in the context of this disorder. Affiliated tissues include testes, uterus and ovary, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A female reproductive system disease that is characterized by an infection of the female reproductive organs.

CDC : 3 Untreated sexually transmitted diseases (STDs) can cause pelvic inflammatory disease (PID), a serious condition, in women. 1 in 8 women with a history of PID experience difficulties getting pregnant. You can prevent PID if you know how to protect yourself.

Wikipedia : 75 Pelvic inflammatory disease, also known as pelvic inflammatory disorder (PID), is an infection of the... more...

Related Diseases for Pelvic Inflammatory Disease

Diseases related to Pelvic Inflammatory Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 324, show less)
# Related Disease Score Top Affiliating Genes
1 salpingitis 32.9 HSPD1 CRP
2 peritonitis 32.7 TLR2 CRP CCL2
3 chlamydia 31.7 TLR4 TLR2 IFNG HSPD1 CRP
4 urethritis 30.6 TLR6 TLR1 HSPD1
5 chlamydia pneumonia 30.6 TLR1 CRP
6 cervicitis 30.5 IL2 HSPD1
7 cystitis 30.1 TLR4 CRP CCL2
8 pyelonephritis 29.9 TLR4 CRP CCL2
9 extrapulmonary tuberculosis 29.7 TLR2 IFNG CCL2
10 secondary progressive multiple sclerosis 29.5 MMP9 IFNG CD40LG CCL2
11 pneumonia 29.4 TLR4 TLR2 CRP CD40LG CCL2
12 myocardial infarction 29.4 TLR4 MMP9 CRP CD40LG CCL2
13 toxic shock syndrome 29.4 TLR4 TLR2 IL2 IFNG
14 common variable immunodeficiency 29.3 TLR2 IL2 IFNG CD40LG
15 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.3 IL2 IFNG CD40LG
16 meningitis 29.0 TLR2 MMP9 IFNG CRP CCL2
17 autoimmune disease 28.6 IL2 IFNG HSPD1 CD40LG
18 proteasome-associated autoinflammatory syndrome 1 28.5 TLR4 TLR2 MMP9 IFNG CRP CCL2
19 bacterial infectious disease 28.1 TLR4 TLR2 TLR1 IFNG HSPD1 CRP
20 fitz-hugh-curtis syndrome 11.8
21 endometritis 11.6
22 pick disease of brain 11.2
23 benign multicystic peritoneal mesothelioma 11.2
24 heart valve disease 11.2
25 ectopic pregnancy 10.8
26 infertility 10.8
27 bacterial vaginosis 10.6
28 prosthetic joint infection 10.6 TLR4 TLR2
29 chronic meningitis 10.5 MMP9 CRP
30 trench fever 10.5 TLR4 TLR2
31 endometriosis 10.5
32 ocular toxoplasmosis 10.5 TLR1 CD40LG
33 vaginal discharge 10.5
34 acute salpingitis 10.5
35 appendicitis 10.5
36 neurosyphilis 10.4 TLR6 TLR2 TLR1
37 bacterial meningitis 10.4 TLR2 MMP9 CRP
38 dental abscess 10.4 TLR4 CRP
39 acute cervicitis 10.4 TLR4 TLR2
40 pyosalpinx 10.4
41 fungal keratitis 10.4 TLR4 TLR2 MMP9
42 suppurative otitis media 10.4 TLR4 TLR2 CRP
43 septic arthritis 10.4 TLR4 TLR2 CRP
44 scrub typhus 10.4 TLR4 TLR2 CRP
45 acute female pelvic peritonitis 10.4
46 keratitis, hereditary 10.4 TLR4 TLR2 MMP9
47 ovarian cancer 10.3
48 sporotrichosis 10.3 IFNG CD40LG
49 japanese spotted fever 10.3 CRP CCL2
50 mycobacterium abscessus 10.3 TLR2 TLR1
51 african tick-bite fever 10.3 IFNG CD40LG
52 scleritis 10.3 MMP9 IFNG
53 endocervicitis 10.3 TLR4 CCL2
54 tuberculous meningitis 10.3 TLR2 MMP9 CCL2
55 congenital cytomegalovirus 10.3 TLR2 CCL2
56 immune deficiency disease 10.2
57 syphilis 10.2
58 chronic pain 10.2
59 carotid artery disease 10.2 MMP9 CRP CCL2
60 mycoplasma pneumoniae pneumonia 10.2 TLR2 IFNG CRP
61 mesenteric lymphadenitis 10.2 TLR2 HSPD1 CRP
62 cerebrovascular disease 10.2 TLR4 MMP9 CRP
63 arteries, anomalies of 10.2 MMP9 CRP CCL2
64 severe combined immunodeficiency 10.2
65 ovarian cyst 10.2
66 endocarditis 10.2 TLR2 HSPD1 CRP
67 aspergillosis 10.2 TLR4 TLR2 IFNG
68 anterior uveitis 10.2 TLR4 CCL2
69 leishmaniasis 10.2 TLR4 TLR2 IFNG
70 campylobacteriosis 10.2 TLR4 IFNG
71 far eastern spotted fever 10.2 IFNG HSPD1
72 trichomoniasis 10.2
73 leukorrhea 10.2
74 extrinsic cardiomyopathy 10.2 TLR4 CRP CCL2
75 vasculitis 10.1 CRP CD40LG CCL2
76 myositis fibrosa 10.1 TLR4 TLR2 IFNG
77 agammaglobulinemia 10.1
78 combined t cell and b cell immunodeficiency 10.1
79 echinococcosis 10.1 TLR4 TLR2 IFNG
80 cat-scratch disease 10.1 IFNG HSPD1
81 diarrhea 10.1
82 actinomycosis 10.1
83 irritable bowel syndrome 10.1
84 ovarian epithelial cancer 10.1
85 cutaneous leishmaniasis 10.1 TLR4 TLR2 IFNG
86 systemic scleroderma 10.1 IFNG CRP CD40LG
87 penicilliosis 10.1 TLR6 TLR4 TLR2 TLR1
88 atherosclerosis susceptibility 10.1 TLR4 CRP CCL2
89 rheumatic disease 10.1 IFNG CRP CD40LG
90 typhoid fever 10.1 TLR4 IFNG CRP
91 colorectal cancer 10.1
92 cervical cancer 10.1
93 parametritis 10.1
94 vaginitis 10.1
95 vulvovaginitis 10.1
96 herpes simplex 10.1
97 47,xyy 10.1
98 bronchiolitis 10.1 TLR4 IFNG CRP
99 chediak-higashi syndrome 10.1
100 agammaglobulinemia, x-linked 10.1
101 hypoglycemia 10.1
102 mouth disease 10.0 TLR4 IFNG CRP
103 pulmonary disease, chronic obstructive 10.0 TLR2 MMP9 CRP CCL2
104 viral meningitis 10.0 IFNG CRP CCL2
105 uremic pruritus 10.0 IL2 CRP
106 exanthem 10.0
107 severe acute respiratory syndrome 10.0 IFNG CRP CCL2
108 temporal arteritis 10.0 IFNG CRP CCL2
109 central nervous system vasculitis 10.0 IFNG CRP
110 interstitial lung disease 10.0 MMP9 IFNG CCL2
111 fungal meningitis 10.0 IFNG CCL2
112 angiostrongyliasis 9.9 MMP9 IL2
113 reactive arthritis 9.9 IFNG HSPD1 CRP
114 chorioamnionitis 9.9 TLR4 MMP9 CRP CCL2
115 q fever 9.9 TLR4 TLR2 TLR1 IFNG
116 melioidosis 9.9 TLR4 TLR2 TLR1 IFNG
117 bacteriuria 9.9 TLR4 TLR1 TIRAP CCL2
118 endometrial cancer 9.9
119 human immunodeficiency virus type 1 9.9
120 tuberculous salpingitis 9.9
121 acute gonococcal cervicitis 9.9
122 anogenital venereal wart 9.9
123 leiomyoma 9.9
124 chronic gonococcal salpingitis 9.9
125 acute cystitis 9.9
126 candidiasis 9.9
127 fallopian tube carcinoma 9.9
128 thrombophlebitis 9.9
129 myofibroma 9.9
130 ureteral obstruction 9.9
131 acute endometritis 9.9
132 ileus 9.9
133 genital herpes 9.9
134 cervix uteri carcinoma in situ 9.9
135 cervical intraepithelial neoplasia 9.9
136 haemophilus influenzae 9.9
137 back pain 9.9
138 anemia, autoimmune hemolytic 9.9
139 ataxia-telangiectasia 9.9
140 ataxia and polyneuropathy, adult-onset 9.9
141 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 9.9
142 autoimmune lymphoproliferative syndrome 9.9
143 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive 9.9
144 immunodeficiency 25 9.9
145 alacrima, achalasia, and mental retardation syndrome 9.9
146 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.9
147 myeloma, multiple 9.9
148 digeorge syndrome 9.9
149 leukemia, chronic lymphocytic 9.9
150 leukocyte adhesion deficiency, type i 9.9
151 hemophagocytic lymphohistiocytosis 9.9
152 immunoglobulin alpha deficiency 9.9
153 scoliosis 9.9
154 mastoiditis 9.9
155 lymphoproliferative syndrome 9.9
156 salmonellosis 9.9
157 hyper ige syndrome 9.9
158 lymphocytic leukemia 9.9
159 dysgammaglobulinemia 9.9
160 telangiectasis 9.9
161 guillain-barre syndrome 9.9
162 polyneuropathy 9.9
163 thrombocytopenia due to platelet alloimmunization 9.9
164 thrombocytopenia 9.9
165 neuroendocrine tumor 9.9
166 ectodermal dysplasia 9.9
167 pustulosis of palm and sole 9.9
168 poliomyelitis 9.9
169 demyelinating polyneuropathy 9.9
170 chronic salpingitis 9.9
171 adenosine deaminase deficiency 9.9
172 hemolytic anemia 9.9
173 paraplegia 9.9
174 lymphopenia 9.9
175 lung disease 9.9
176 psoriasis 9.9
177 albinism 9.9
178 atypical mycobacteriosis, familial 9.9
179 chronic inflammatory demyelinating polyneuropathy 9.9
180 glioma 9.9
181 leukemia, b-cell, chronic 9.9
182 multifocal motor neuropathy 9.9
183 spinal cord injury 9.9
184 glial tumor 9.9
185 boutonneuse fever 9.9 TLR4 IL2
186 relapsing polychondritis 9.9 IFNG CRP
187 toxoplasmosis 9.9 TLR4 TLR2 IFNG CD40LG
188 autoimmune disease of musculoskeletal system 9.9 IL2 CRP CD40LG
189 fixed drug eruption 9.9 IL2 IFNG
190 central nervous system disease 9.8 MMP9 IFNG CCL2
191 berylliosis 9.8 IL2 IFNG
192 myd88 deficiency 9.8 TLR6 TLR4 TLR2 TLR1 TIRAP
193 irak4 deficiency 9.8 TLR6 TLR4 TLR2 TLR1 TIRAP
194 atopic keratoconjunctivitis 9.8 IL2 IFNG
195 kawasaki disease 9.8 MMP9 HSPD1 CRP CCL2
196 nervous system disease 9.8 MMP9 IFNG CRP CCL2
197 demyelinating disease 9.8 MMP9 IFNG CD40LG CCL2
198 adenomyosis 9.8
199 body mass index quantitative trait locus 9 9.8
200 body mass index quantitative trait locus 8 9.8
201 body mass index quantitative trait locus 4 9.8
202 body mass index quantitative trait locus 10 9.8
203 body mass index quantitative trait locus 7 9.8
204 diabetes mellitus, ketosis-prone 9.8
205 major affective disorder 8 9.8
206 body mass index quantitative trait locus 12 9.8
207 major affective disorder 9 9.8
208 body mass index quantitative trait locus 14 9.8
209 body mass index quantitative trait locus 18 9.8
210 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 9.8
211 body mass index quantitative trait locus 11 9.8
212 insulin-like growth factor i 9.8
213 familial mediterranean fever 9.8
214 uterus bicornis bicollis with partial vaginal septum and unilateral hematocolpos with ipsilateral renal agenesis 9.8
215 renal hypodysplasia/aplasia 1 9.8
216 ureterocele 9.8
217 pelvic organ prolapse 9.8
218 body mass index quantitative trait locus 19 9.8
219 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
220 body mass index quantitative trait locus 20 9.8
221 small cell carcinoma 9.8
222 paragonimiasis 9.8
223 strongyloidiasis 9.8
224 salpingo-oophoritis 9.8
225 hydronephrosis 9.8
226 endometriosis of ovary 9.8
227 portal vein thrombosis 9.8
228 neutropenia 9.8
229 dysentery 9.8
230 pancytopenia 9.8
231 chancroid 9.8
232 inclusion conjunctivitis 9.8
233 interstitial cystitis 9.8
234 mental depression 9.8
235 pneumothorax 9.8
236 heart septal defect 9.8
237 histoplasmosis 9.8
238 atrial heart septal defect 9.8
239 hepatitis b 9.8
240 constipation 9.8
241 vulvovaginal candidiasis 9.8
242 nocardiosis 9.8
243 gastroenteritis 9.8
244 myoma 9.8
245 proctitis 9.8
246 chronic granulomatous disease 9.8
247 bipolar disorder 9.8
248 skin disease 9.8
249 sleep disorder 9.8
250 lice infestation 9.8
251 conjunctivitis 9.8
252 acquired immunodeficiency syndrome 9.8
253 adenoma 9.8
254 diverticulitis 9.8
255 peptic ulcer disease 9.8
256 peptic ulcer perforation 9.8
257 myocarditis 9.8
258 scabies 9.8
259 intestinal obstruction 9.8
260 paralytic ileus 9.8
261 in situ carcinoma 9.8
262 keratoconjunctivitis 9.8
263 miliary tuberculosis 9.8
264 hypereosinophilic syndrome 9.8
265 cytokine deficiency 9.8
266 infectious myocarditis 9.8
267 meralgia paresthetica 9.8
268 ovarian remnant syndrome 9.8
269 splenomegaly 9.8
270 streptococcal group a invasive disease 9.8
271 depression 9.8
272 longitudinal vaginal septum 9.8
273 transient pseudohypoaldosteronism 9.8
274 streptococcal toxic-shock syndrome 9.8
275 precursor t-cell acute lymphoblastic leukemia 9.8
276 intestinal disease 9.8 TLR4 IL2 CRP
277 vascular disease 9.7 MMP9 HSPD1 CRP CCL2
278 pulmonary tuberculosis 9.7 TLR2 IL2 IFNG
279 lepromatous leprosy 9.7 TLR2 IL2 IFNG
280 multicentric castleman disease 9.7 IFNG CRP
281 parasitic protozoa infectious disease 9.7 TLR2 IL2 IFNG
282 urinary system disease 9.7 IL2 CRP CCL2
283 connective tissue disease 9.7 IFNG HSPD1 CD40LG
284 tropical spastic paraparesis 9.7 MMP9 IL2 IFNG
285 clonorchiasis 9.6 IL2 IFNG
286 measles 9.6 TLR2 IL2 IFNG
287 schistosomiasis 9.6 IL2 IFNG CD40LG
288 variola major 9.6 TLR4 IL2 IFNG
289 invasive aspergillosis 9.6 TLR6 TLR4 TLR2 TLR1 IFNG
290 tetanus 9.6 IL2 IFNG CD40LG
291 colitis 9.6 TLR4 IL2 IFNG
292 leptospirosis 9.6 TLR2 TLR1 IFNG CRP CCL2
293 crohn's colitis 9.6 IL2 IFNG
294 viral infectious disease 9.6 IL2 IFNG CD40LG
295 autoimmune uveitis 9.5 IL2 IFNG CCL2
296 autoimmune disease of central nervous system 9.5 IL2 IFNG CCL2
297 pulmonary sarcoidosis 9.5 IL2 IFNG CCL2
298 arteriosclerosis 9.5 TLR4 MMP9 HSPD1 CRP CCL2
299 mycobacterium tuberculosis 1 9.4 TLR4 TLR2 TLR1 IFNG HSPD1
300 paracoccidioidomycosis 9.4 TLR4 TLR2 IL2 IFNG
301 immune system disease 9.4 TLR6 TLR1 IL2 IFNG
302 visceral leishmaniasis 9.4 TLR4 TLR2 IL2 IFNG
303 large intestine cancer 9.4 MMP9 IL2 IFNG CRP
304 ulcerative colitis 9.3 TLR4 IL2 IFNG CRP
305 trypanosomiasis 9.3 TLR2 IL2 IFNG CCL2
306 multiple sclerosis 9.3 MMP9 IL2 IFNG CCL2
307 pleurisy 9.3 IL2 IFNG CRP CCL2
308 bone inflammation disease 9.3 IL2 IFNG CRP CCL2
309 leprosy 3 9.3 TLR2 IL2 IFNG HSPD1
310 testicular disease 9.3 TLR2 IL2 IFNG HSPD1
311 periodontitis 9.2 TLR4 TLR2 MMP9 IFNG CRP CCL2
312 lyme disease 9.2 TLR6 TLR2 TLR1 MMP9 HSPD1 CRP
313 inflammatory bowel disease 9.1 TLR4 TLR2 IL2 IFNG CRP
314 gastrointestinal system disease 9.1 TLR4 MMP9 IL2 IFNG CRP
315 brucellosis 9.1 TLR4 IL2 IFNG CRP CD40LG
316 asthma 9.0 TLR6 MMP9 IFNG CHI3L1 CD40LG CCL2
317 chagas disease 9.0 TLR4 TLR2 IL2 IFNG CCL2
318 behcet syndrome 8.9 TLR4 IL2 IFNG HSPD1 CRP
319 filariasis 8.8 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
320 respiratory system disease 8.7 TLR4 MMP9 IL2 IFNG CRP CCL2
321 primary bacterial infectious disease 8.7 TLR4 TLR2 IL2 IFNG HSPD1 CRP
322 systemic lupus erythematosus 8.4 TLR4 TLR2 IL2 IFNG CRP CD40LG
323 malaria 7.9 TLR4 TLR2 TIRAP MMP9 IL2 IFNG
324 rheumatoid arthritis 7.8 TLR4 TLR2 MMP9 IL2 IFNG CRP

Comorbidity relations with Pelvic Inflammatory Disease via Phenotypic Disease Network (PDN): (showing 1, show less)


Acute Cystitis

Graphical network of the top 20 diseases related to Pelvic Inflammatory Disease:



Diseases related to Pelvic Inflammatory Disease

Symptoms & Phenotypes for Pelvic Inflammatory Disease

UMLS symptoms related to Pelvic Inflammatory Disease:


fever, pruritus, pelvic pain

MGI Mouse Phenotypes related to Pelvic Inflammatory Disease:

46 (showing 4, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.86 CD40LG CRP IFNG IL2 MMP9 TIRAP
2 hematopoietic system MP:0005397 9.85 CD40LG CHI3L1 IFNG IL2 MMP9 TIRAP
3 immune system MP:0005387 9.73 CCL2 CD40LG CHI3L1 CRP IFNG IL2
4 reproductive system MP:0005389 9.17 CD40LG HSPD1 IFNG IL2 MMP9 TLR4

Drugs & Therapeutics for Pelvic Inflammatory Disease

DrugBank drugs 16 :

(showing 6, show less)
# Drug Name Indication DrugBank ID
1 Azithromycin Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label]. Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. **Adults**: Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage. Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_. Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. **Pediatric Patients** Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. DB00207
2 Cefotaxime Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery. DB00493
3 Cefotetan For prophylaxis and treatment of bacterial infections. DB01330
4 Cefoxitin For the treatment of serious infections caused by susceptible strains microorganisms. DB01331
5 Piperacillin For the treatment of polymicrobial infections. DB00319
6 Tazobactam Tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action, treating susceptible infections. As with any other antibiotic, tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drug. **Tazobactam-piperacillin** When combined with piperacillin, it is used to treat a variety of infections, including those caused by aerobic and facultative gram-positive and gram-negative bacteria, in addition to gram-positive and gram-negative anaerobes. Some examples of infections treated with piperacillin-tazobactam include cellulitis, diabetic foot infections, appendicitis, and postpartum endometritis infections.[L4417] Certain gram-negative bacilli infections with beta-lactamase producing organisms cannot be treated with piperacillin-tazobactam, due to a gene mutation conferring antibiotic resistance.[A179266] **Tazobactam-ceftolozane** Tazobactam-ceftolozane combined with metronidazole is used to treat complicated urinary tract infections (UTI) and complicated intra-abdominal infections, as well as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.[FDA label]. This combination increases efficacy against infections with gram-negative bacilli.[A7657] DB01606

Drugs for Pelvic Inflammatory Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 85, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
2
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
3
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
7
Gemifloxacin Approved, Investigational Phase 4 175463-14-6 9571107 5464436
8
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Metronidazole Approved Phase 4 443-48-1 4173
12
Azithromycin Approved Phase 4 83905-01-5 447043 55185
13
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
14 Contraceptives, Oral Phase 4
15 Contraceptives, Oral, Combined Phase 4
16 Norgestimate, ethinyl estradiol drug combination Phase 4
17 Estradiol 3-benzoate Phase 4
18 Estradiol 17 beta-cypionate Phase 4
19 Alkylating Agents Phase 4
20 Gentamicins Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Renal Agents Phase 4
23 Topoisomerase Inhibitors Phase 4
24 Anti-Infective Agents, Urinary Phase 4
25 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
26 Acidophilus Phase 4
27 Antibiotics, Antitubercular Phase 4
28 Antitubercular Agents Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Bacterial Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Anti-Infective Agents Phase 4
34 Antimalarials Phase 4
35 Gastrointestinal Agents Phase 4
36 Cathartics Phase 4
37 Carboxymethylcellulose Sodium Phase 4
38 Laxatives Phase 4
39
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
40
Copper Approved, Investigational Phase 3 7440-50-8 27099
41
Cefixime Approved, Investigational Phase 3 79350-37-1 54362 5362065
42 Contraceptive Agents Phase 3
43 Hormones Phase 3
44
Clavulanate Approved, Vet_approved Phase 2 58001-44-8 5280980
45
Ticarcillin Approved, Investigational, Vet_approved Phase 2 34787-01-4 36921
46
Ertapenem Approved, Investigational Phase 2 153832-46-3 150610
47
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
48 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
49 beta-Lactamase Inhibitors Phase 2
50 diuretics Phase 2
51 Pharmaceutical Solutions Phase 1
52
Curcumin Approved, Experimental, Investigational 458-37-7 969516
53
Clarithromycin Approved 81103-11-9 84029
54
Amoxicillin Approved, Vet_approved 26787-78-0 33613
55
Telithromycin Approved 191114-48-4 5462516 70789201
56
Cefuroxime Approved 55268-75-2 5361202 5479529
57
Levonorgestrel Approved, Investigational 797-63-7, 17489-40-6 13109
58
Aspartic acid Approved, Nutraceutical 56-84-8 5960
59 Deslorelin Investigational, Vet_approved 57773-65-6
60 Analgesics, Non-Narcotic
61 Peripheral Nervous System Agents
62 Analgesics
63 Anti-Inflammatory Agents, Non-Steroidal
64 Antirheumatic Agents
65 Cytochrome P-450 CYP3A Inhibitors
66 Fluoroquinolones
67 Amoxicillin-Potassium Clavulanate Combination
68 cefuroxime axetil
69 Liver Extracts
70 Triptorelin Pamoate
71 Chorionic Gonadotropin
72 Gonadotropins, Pituitary
73 N-Methylaspartate
74 alanine
75 Anti-Retroviral Agents
76 Immunologic Factors
77 Complement System Proteins
78 Micronutrients
79 Nutrients
80 Trace Elements
81 Omega 3 Fatty Acid
82 Antioxidants
83 Protective Agents
84 Vitamins
85 Anesthetics

Interventional clinical trials:

(showing 66, show less)
# Name Status NCT ID Phase Drugs
1 Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials Completed NCT01799356 Phase 4 Moxifloxacin;Ofloxacin;Metronidazole
2 Phase 4 Study of Azitromicin in the Treatment of PID Completed NCT01241110 Phase 4 Ofloxacin group A, Azitromycin group B;azitromycin
3 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
4 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
5 Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea Completed NCT00926796 Phase 4 Azithromycin;Gentamicin;Gemifloxacin
6 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Recruiting NCT03391440 Phase 4 morinidazole
7 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
8 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Recruiting NCT03380793 Phase 4 morinidazole
9 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
10 A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome):a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study Not yet recruiting NCT04031664 Phase 4 Qianjin Capsule of Gynaecology
11 A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation):a Randomized, Double Blind, Parallel Control of Positive Drugs,Multi-center Clinical Study Not yet recruiting NCT04035785 Phase 4 Kangfu Anti-inflammatory Suppository
12 Randomized, Open-label, Multicenter Study of Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Not yet recruiting NCT03532464 Phase 4 azithromycin;doxycycline
13 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
14 Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID) Completed NCT00683865 Phase 3 Ofloxacin;Avelox (Moxifloxacin, BAY12-8039)
15 A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 Days in Subjects With an Uncomplicated Pelvic Inflammatory Disease (PID). Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study) Completed NCT00453349 Phase 3 Moxifloxacin (Avelox, BAY12-8039);Levofloxacin & Metronidazole
16 A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy Completed NCT00871494 Phase 3 Azithromycin
17 A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone Completed NCT01473836 Phase 3 Metronidazole;Ceftriaxone sodium
18 Home Screening for Chlamydia Surveillance Completed NCT00177437 Phase 3
19 A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept™, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability Recruiting NCT03633799 Phase 3 VeraCept
20 A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology Terminated NCT01072136 Phase 3 Azithromycin;Cefixime
21 Clinical Promotion Research of Complex Treatment With TCM to Diagnosis and Treatment on Different Syndrome Types of Pelvic Inflammatory Disease Sequelae Unknown status NCT02972151 Phase 2 Comprehensive treatment of TCM
22 The Importance of Anti-anaerobic Therapy for Acute PID Completed NCT01160640 Phase 2 Ceftriaxone;Doxycycline;Metronidazole;Placebo Oral Capsule
23 A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients Completed NCT00092170 Phase 2 MK0826, ertapenem sodium;Comparator: Ticarcillin/Clavulanate
24 MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study Completed NCT01911702 Phase 2
25 The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation Recruiting NCT03251560 Phase 2 Fuke Qianjin capsule;Placebo oral capsule
26 Intrauterine Infusion of Autologous Platelet-Rich Plasma (PRP) in Women With Thin Endometrium Undergoing Embryo-transfer. Recruiting NCT03067623 Phase 2 PRP
27 Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers Completed NCT03054402 Phase 1 BAY1834845;Placebo
28 Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study Unknown status NCT03016039
29 Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users Unknown status NCT03261804
30 Rate of Pelvic Inflammatory Disease and Tubo-ovarian Abscess at SMH Completed NCT00783419
31 Improving Primary Care Follow-up for Adolescents With PID: A Randomized Controlled Trial Using Text Message Reminders Completed NCT01299259
32 To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy Completed NCT01842100 Universal antibiotic prophylaxis
33 Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis. Completed NCT01236131
34 Drug Use Investigation Of Azithromycin Iv Completed NCT01671280 Azithromycin IV
35 Immunopathogenesis of Chlamydia Trachomatis Infection Completed NCT00607659
36 Technology Enhanced Community Health Nursing (TECH-N) to Prevent Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease Completed NCT01640379
37 Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease Completed NCT00115388
38 Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success Completed NCT01793584
39 Zithromac Iv Special Investigation For Legionella Infection. Completed NCT01784770 Azithromycin IV
40 Recurrent Bacterial Vaginosis (RBV): Efficiency of Metronidazole in Comparison to Metronidazole and Intravaginal Acidifying Gel: A Randomized Investigator-blinded Controlled Trial Completed NCT00545181 Vaginal acidifying gel (RepHresh);Metronidazole control
41 Longitudinal Study of Vaginal Flora Completed NCT00340275
42 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158
43 Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population Completed NCT01434173 Moxifloxacin (Avelox, BAY12-8039);Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
44 The Measurement of Endometrial Volume and Sub-endometrial Vascularity to Replace the Traditional Endometrial Thickness as Predictors of In-vitro Fertilization Success Completed NCT02381821 GnRH agonist
45 Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis Completed NCT00970749
46 Quick Start Insertion of Mirena and ParaGard Intrauterine Contraceptive Devices Completed NCT01730911
47 Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women. - A Randomised Control Trial Completed NCT00283127
48 Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa Completed NCT01721798
49 HIV Risk Reduction for Women Reporting Intimate Partner Violence Completed NCT01695694
50 Evaluation of an Inpatient Sexual Risk Behavior Assessment Program Completed NCT03502226
51 The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow. Completed NCT00489463
52 Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women Completed NCT02272231
53 Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract Completed NCT00299663
54 Complement Diagnosis of Acute Appendicitis Completed NCT03450642
55 Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase of Infertile Women With Natural Cycles Completed NCT01533350
56 Diagnostic Yield of Narrow Band Imaging (NBI) and Standard Visible White Light Laparoscopy for the Detection of Endometriosis Completed NCT01464775
57 Prospective Data Collection of Patients With Pelvic Inflammatory Disease Recruiting NCT02567812
58 Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID Recruiting NCT03828994
59 Prevention of Diseases Induced by Chlamydia Trachomatis Recruiting NCT02904811
60 Efficacy of Resistive Capacitive Monopolar Radiofrequency in the Physiotherapeutic Treatment of Chronic Pelvic Pain: Randomized Clinical Trial. Recruiting NCT03797911
61 STD Testing in Outpatient Practices-The STOP STDs Study Recruiting NCT03246815
62 European Active Surveillance Study of LCS12 Recruiting NCT02146950
63 Effect of an Anti-inflammatory Diet on the Nutritional Status and Cytokine Expression of Patients With Locally Advanced Cervical Cancer: A Randomized Clinical Trial Recruiting NCT03994055
64 Comparative Study of Hysteroscopic Versus Laparoscopic Tubal Occlusion in Cases of Communicating Hydrosalpinx and Planning for IVF Not yet recruiting NCT04037813
65 Improving the Detection of STIs in the Pediatric Emergency Department: A Pragmatic Trial Not yet recruiting NCT03715335
66 A Randomized, Controlled Trial of Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis Terminated NCT00997516

Search NIH Clinical Center for Pelvic Inflammatory Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azithromycin
Cefotaxime
Cefotetan
Cefoxitin
Piperacillin
Tazobactam

Cochrane evidence based reviews: pelvic inflammatory disease

Genetic Tests for Pelvic Inflammatory Disease

Anatomical Context for Pelvic Inflammatory Disease

MalaCards organs/tissues related to Pelvic Inflammatory Disease:

41
Testes, Uterus, Ovary, Liver, Colon, Breast, Neutrophil

Publications for Pelvic Inflammatory Disease

Articles related to Pelvic Inflammatory Disease:

(showing 3834, show less)
# Title Authors PMID Year
1
Impact of endometritis on post-partum ovarian cyclicity in dairy cows. 17
31113569 2019
2
Matrine alleviates Staphylococcus aureus lipoteichoic acid-induced endometritis via suppression of TLR2-mediated NF-κB activation. 17
30822611 2019
3
Operative vaginal delivery and post-partum infection. 17
30992125 2019
4
Chlamydia pneumoniae as a respiratory pathogen. 9 38
11861211 2002
5
Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease. 9 38
9498452 1998
6
Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin. 9 38
18475331 1993
7
Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens. 9 38
2205652 1990
8
Ultrasonographic and multimodal imaging of pediatric genital female diseases. 38
30778893 2019
9
The Influencing Factors of Venous Intravasation During Transvaginal Four-dimensional Hysterosalpingo-contrast Sonography With SonoVue. 38
31201020 2019
10
Current usage of qualitative research in female pelvic pain: a systematic review. 38
31201537 2019
11
An update on prevalence, diagnosis, treatment and emerging issues of genital mycoplasma infection in Indian women: A narrative review. 38
31389367 2019
12
Xanthogranulomatous Salpingitis. 38
31433377 2019
13
No. 385-Indications for Pelvic Examination. 38
31331610 2019
14
Intravasation Affects the Diagnostic Image Quality of Transvaginal 4-Dimensional Hysterosalpingo-Contrast Sonography With SonoVue. 38
30597629 2019
15
Efficacy of a Technology-Enhanced Community Health Nursing Intervention vs Standard of Care for Female Adolescents and Young Adults With Pelvic Inflammatory Disease: A Randomized Clinical Trial. 38
31390037 2019
16
Fitz-Hugh-Curtis syndrome resulting in nutmeg liver on computed tomography. 38
31193761 2019
17
Effect of Time of Day of Infection on Chlamydia Infectivity and Pathogenesis. 38
31388084 2019
18
Mycoplasma genitalium incidence, persistence, concordance between partners and progression: systematic review and meta-analysis. 38
31055469 2019
19
Reliability of administrative data to identify sexually transmitted infections for population health: a systematic review. 38
31399425 2019
20
An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. 38
31369673 2019
21
Factors associated with anorectal Chlamydia trachomatis or Neisseria gonorrhoeae test positivity in women: a systematic review and meta-analysis. 38
31097677 2019
22
Higher Prevalence of Endometrial Polyps in Patients with Fallopian Tube Obstruction: A Case-control Study. 38
30273685 2019
23
A case of obstructed hemivagina and ipsilateral renal anomaly syndrome complicated with pyometra: tips and tricks for laparoscopic hemihysterectomy. 38
31126713 2019
24
Therapeutic Impact of Initial Treatment for Chlamydia trachomatis Among Patients With Pelvic Inflammatory Disease: A Retrospective Cohort Study Using a National Inpatient Database in Japan. 38
30312389 2019
25
Concurrency of splenomegaly and numerous enlarged mesenteric and retroperitoneal lymph nodes in a patient with pelvic inflammatory disease caused by Edwardsiella tarda: Mimicking lymphoma. 38
30887633 2019
26
Self-Reported Infertility and Associated Pelvic Inflammatory Disease Among Women of Reproductive Age-National Health and Nutrition Examination Survey, United States, 2013-2016. 38
31194716 2019
27
[Guideline of pelvic inflammatory disease (2019 revised edition)]. 38
31365954 2019
28
Mycoplasma genitalium: A Review. 38
31329090 2019
29
Surgical Management and Prevention of Ovarian Remnant. 38
30414999 2019
30
Evaluation of Positron Emission Tomography and Contrast-Enhanced Computed Tomography Scan in Nodal Staging of Early Operable Uterine Cancers. 38
31293295 2019
31
Management of gonorrhoea in a hospital network: are we following best practice? 38
31292064 2019
32
The predictive role of CA-125 in the management of tubo-ovarian abscess. A retrospective study. 38
31082739 2019
33
Efficacy of Antibiotic Prophylaxis for Hysteroscopy: A Meta-Analysis of Randomized Trials. 38
31302246 2019
34
Prevalence and Risk Factors of Trichomonas vaginalis Among Female Sexual Workers in Nairobi, Kenya. 38
31194717 2019
35
The human tubal lavage proteome reveals biological processes that may govern the pathology of hydrosalpinx. 38
31222072 2019
36
Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. 38
30606817 2019
37
Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study. 38
30871933 2019
38
Protective effects of Asiatic acid against pelvic inflammatory disease in rats. 38
31086602 2019
39
Laparoscopic Compared With Open Surgery for Severe Pelvic Inflammatory Disease and Tubo-Ovarian Abscess. 38
31135738 2019
40
Benefits of second-look laparoscopy in the management of pelvic inflammatory disease. 38
30910760 2019
41
[Effect of Fuyanshu Capsules combined with antibiotics on inflammatory factors in patients with pelvic inflammatory disease]. 38
31359734 2019
42
Pelvic Inflammatory Disease in a Pediatric Emergency Department: Epidemiology and Treatment. 38
28441241 2019
43
Partner Notification, Treatment, and Subsequent Condom Use After Pelvic Inflammatory Disease: Implications for Dyadic Intervention With Urban Youth. 38
31165630 2019
44
Comprehensive characterization and quantification of multiple components in Dan-Huang-Qu-Yu capsule using a multivariate data processing approach based on microwave-assisted extraction with UHPLC and Q Exactive quadrupole-orbitrap high-resolution mass spectrometry. 38
30942527 2019
45
Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient. 38
30556401 2019
46
Tubo-ovarian abscess with sepsis in a nonagenarian woman: a case report and literature review. 38
31216992 2019
47
Selected Immunological Mediators and Cervical Microbial Signatures in Women with Chlamydia trachomatis Infection. 38
31164450 2019
48
[Follow-up and counselling after pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 38
30878686 2019
49
Ultrasound of Pelvic Pain in the Nonpregnant Woman. 38
30928080 2019
50
[Diagnosis of pelvic inflammatory disease: Clinical, paraclinical, imaging and laparoscopy criteria. CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 38
30878687 2019
51
[Management of tubo-ovarian abscesses and complicated pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 38
30880246 2019
52
Laparoscopic Compared With Open Surgery for Severe Pelvic Inflammatory Disease and Tubo-Ovarian Abscess. 38
31083118 2019
53
[Treatment of uncomplicated pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. 38
30878689 2019
54
Acute Pelvic Pain. 38
30940367 2019
55
Suspected gonorrhea and chlamydia: Incidence and utilization of empiric antibiotics in a health system emergency department. 38
30119987 2019
56
The compatibility of six alkaloids in ermiao pill explored by a comparative pharmacokinetic and network pharmacological study. 38
30756408 2019
57
[Pelvic Inflammatory Diseases: Updated Guidelines for Clinical Practice - Short version]. 38
30880245 2019
58
Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. 38
30894687 2019
59
Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. 38
30753898 2019
60
The Dangers of Hymenotomy for Imperforate Hymen: A Case of Iatrogenic Pelvic Inflammatory Disease with Pyosalpinx. 38
30974214 2019
61
Why a Pelvic Exam is Needed to Diagnose Cervicitis and Pelvic Inflammatory Disease. 38
30902176 2019
62
Pelvic inflammatory disease: An unusual cause of acute intestinal obstruction. 38
30982548 2019
63
Please Be Careful with Me: Discrepancies between Adolescent Expectations and Clinician Perspectives on the Management of Pelvic Inflammatory Disease. 38
30974212 2019
64
Chlamydia trachomatis in women with pelvic inflammatory disease (PID): report from a tertiary center in eastern Nepal. 38
30755106 2019
65
Trends in diagnosis of pelvic inflammatory disease in an Australian sexual health clinic, 2002-16: before and after clinical audit feedback. 38
30940330 2019
66
Streptococcal Toxic Shock Syndrome After Insertion of a Levonorgestrel Intrauterine Device. 38
30981616 2019
67
Pediatric pyosalpinx without sexually transmitted infection: A report of 3 cases. 38
30815048 2019
68
Actinomycotic Endometritis. 38
29369919 2019
69
Improving Women's Health and Combatting Sexually Transmitted Infections Through Expedited Partner Therapy. 38
30741802 2019
70
Abdominal Actinomycosis Mimicking Colon Cancer. 38
31060658 2019
71
[Pelvic inflammatory disease is a rare cause of acute abdomen in a child]. 38
30869072 2019
72
Infections caused by Chlamydia trachomatis (including lymphogranuloma venereum) and Mycoplasma genitalium. 38
30878312 2019
73
Discovery of anti-inflammatory terpenoids from Mallotus conspurcatus croizat. 38
30445108 2019
74
Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. 38
29790947 2019
75
Risk of ectopic pregnancy and tubal infertility following gonorrhoea and chlamydia infections. 38
30778532 2019
76
[Acute Pelvic pain in women-gynecological causes]. 38
30519765 2019
77
The first reported case of pelvic inflammatory disease caused by Actinobaculum massiliense. 38
30439470 2019
78
Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials. 38
30341232 2019
79
Clinical Features and Therapeutic Response in Women Meeting Criteria for Presumptive Treatment for Pelvic Inflammatory Disease Associated With Mycoplasma genitalium. 38
30640861 2019
80
Role of general gynaecologists in the prevention of infertility. 38
30837119 2019
81
A novel fluorescence method for activity assay and drug screening of T4 PNK by coupling rGO with ligase reaction. 38
30566137 2019
82
Emergent genital infection by Leptotrichia trevisanii. 38
29980937 2019
83
Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention. 38
30321529 2019
84
Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present. 38
31015819 2019
85
A unique insight into the MiRNA profile during genital chlamydial infection. 38
30777008 2019
86
Use of Human Fallopian Tube Organ in Culture (FTOC) and Primary Fallopian Tube Epithelial Cells (FTEC) to Study the Biology of Neisseria gonorrhoeae Infection. 38
31119635 2019
87
The Risk of Gynecologic and Urinary Tract Cancer with Pelvic Inflammatory Disease: A Population-Based Cohort Study. 38
30662522 2019
88
TLR3 deficiency exacerbates the loss of epithelial barrier function during genital tract Chlamydia muridarum infection. 38
30625140 2019
89
Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion. 38
30824209 2019
90
Medicinal Chemistry of Alternative Therapeutics: Novelty and Hopes with Genus Ammannia. 38
30977452 2019
91
Analysis of Host Responses to Neisseria gonorrhoeae Using a Human Three-Dimensional Endometrial Epithelial Cell Model. 38
31119633 2019
92
Association of pelvic inflammatory disease (PID) with ectopic pregnancy and preterm labor in Taiwan: A nationwide population-based retrospective cohort study. 38
31408465 2019
93
CPAF, HSP60 and MOMP antigens elicit pro-inflammatory cytokines production in the peripheral blood mononuclear cells from genital Chlamydia trachomatis-infected patients. 38
30477893 2019
94
A renewed tool kit to explore Chlamydia pathogenesis: from molecular genetics to new infection models. 38
31249676 2019
95
The Anti-Inflammatory Effect of Feiyangchangweiyan Capsule and Its Main Components on Pelvic Inflammatory Disease in Rats via the Regulation of the NF-κB and BAX/BCL-2 Pathway. 38
31312226 2019
96
Is There a Benefit to Culturing Intra-Uterine Devices in Pelvic Inflammatory Disease? 38
30045030 2019
97
The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. 38
29729331 2019
98
Treatment cost and costing model of obstetric complications at a hospital in Myanmar. 38
30893318 2019
99
Biofilm in Genital Ecosystem: A Potential Risk Factor for Chlamydia trachomatis Infection. 38
30805068 2019
100
The Pathogenic Neisseria Use a Streamlined Set of Peptidoglycan Degradation Proteins for Peptidoglycan Remodeling, Recycling, and Toxic Fragment Release. 38
30766523 2019
101
Bacterial vaginosis: a primer for clinicians. 38
30424704 2019
102
Simultaneous profiling of sexually transmitted bacterial pathogens, microbiome, and concordant host response in cervical samples using whole transcriptome sequencing analysis. 38
30854394 2019
103
Captive uterus syndrome: An unrecognized complication of cesarean sections? 38
30593433 2019
104
Laparoscopic Surgery for Ovarian Cyst Infection with Avoidance of Ureteral Injury and Uterine Perforation following Intrauterine Insemination after Abdominal Modified Radical Trachelectomy. 38
31183231 2019
105
Ethnic Minority Status and Experiences of Infertility in Female Veterans. 38
30481107 2019
106
Survey of Obstetrician-gynecologists in the United States About Trichomoniasis, 2016. 38
29994936 2019
107
Swiss gynecologists' opinions and perceptions concerning the use of intrauterine devices by nulliparous and multiparous women: an online survey study. 38
30881144 2019
108
A rare case of Fitz-Hugh-Curtis syndrome caused by Chlamydia trachomatis in an HIV-positive male patient. 38
30728975 2019
109
Tubo-Ovarian Abscesses: Epidemiology and Predictors for Failed Response to Medical Management in an Asian Population. 38
31274977 2019
110
Advancing the public health applications of Chlamydia trachomatis serology. 38
29983342 2018
111
Cervical Cancer Induction Enhancement Potential of Chlamydia Trachomatis: A Systematic Review. 38
29356877 2018
112
[Intrauterine contraception: CNGOF Contraception Guidelines]. 38
30429071 2018
113
A challenging case of pelvic inflammatory disease due to miliary tuberculosis. 38
30117595 2018
114
The Additive Value of Pelvic Examinations to History in Predicting Sexually Transmitted Infections for Young Female Patients With Suspected Cervicitis or Pelvic Inflammatory Disease. 38
30251627 2018
115
[Clinical application evaluation and revision suggestions of clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for pelvic inflammatory disease]. 38
30717512 2018
116
Cost-Benefit Analysis of a Chlamydia trachomatis Vaccine Program in Adolescent Girls in the United States. 38
28992068 2018
117
[Sexually transmitted infections and male fertility]. 38
30406812 2018
118
Chlamydia ascites: a call for sexually transmitted infection testing. 38
30580299 2018
119
Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis. 38
30300019 2018
120
The Gynecologic Health Consequences of Chlamydia trachomatis Infection in Military Servicewomen. 38
31003249 2018
121
Ozone therapy ameliorates inflammation and endometrial injury in rats with pelvic inflammatory disease. 38
30257358 2018
122
Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. 38
30269307 2018
123
Rates of pelvic inflammatory disease and ectopic pregnancy in Australia, 2009-2014: ecological analysis of hospital data. 38
29720385 2018
124
Comparison of three serological assays to measure antibody response to Chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease. 38
30049256 2018
125
Comparison of the prevalence of adhesions at the time of diagnostic laparoscopy for infertility between patient who had open myomectomy and those who had no previous pelvic-abdominal surgery or pelvic inflammatory disease. 38
30417838 2018
126
Trends in Pelvic Inflammatory Disease Among American Indian and Alaska Native Women, Indian Health Service, 2001-2015. 38
30252529 2018
127
Repeat Chlamydia Diagnoses Increase the Hazard of Pelvic Inflammatory Disease among US Army Women: A Retrospective Cohort Analysis. 38
29870505 2018
128
Evaluation of pelvic inflammatory disease potential in cholinesterase inhibitor pesticide-exposed females. 38
28497326 2018
129
Pelvic inflammatory disease: management requires a patient, prudent, prejudice-free provider. 38
30422800 2018
130
The two-sided role of the vaginal microbiome in Chlamydia trachomatis and Mycoplasma genitalium pathogenesis. 38
30149363 2018
131
Incidence and sequelae of acute pelvic inflammatory disease among active component females, U.S. Armed Forces, 1996-2016. 38
31066569 2018
132
Endocervical and Neutrophil Lipoxygenases Coordinate Neutrophil Transepithelial Migration to Neisseria gonorrhoeae. 38
29905822 2018
133
Capsid protein Vp1 from chlamydiaphage φCPG1 effectively alleviates cytotoxicity induced by Chlamydia trachomatis. 38
30233675 2018
134
Leptrotrichia Amnionii, an emerging pathogen of postpartum endometritis. 38
29078736 2018
135
Association of Pelvic Inflammatory Disease with Risk of Endometriosis: A Nationwide Cohort Study Involving 141,460 Individuals. 38
30352985 2018
136
Microbiota changes impact on sexually transmitted infections and the development of pelvic inflammatory disease. 38
29452257 2018
137
Characterization of pelvic and cervical microbiotas from patients with pelvic inflammatory disease. 38
30113305 2018
138
Assessing the Accuracy of Physician Self-disclosed PID Reporting: A Comparison of Data from a Physician Survey and Actual PID Case Reports from a State Surveillance System. 38
30324002 2018
139
A rare case of large pyosalpinx in an elderly patient with well-controlled type 2 diabetes mellitus: a case report. 38
30290835 2018
140
ACOG Committee Opinion No. 754 Summary: The Utility of and Indications for Routine Pelvic Examination. 38
30247359 2018
141
ACOG Committee Opinion No. 754: The Utility of and Indications for Routine Pelvic Examination. 38
30247363 2018
142
Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids. 38
30085898 2018
143
Risk factors for Mycoplasma genitalium endometritis and incident infection: a secondary data analysis of the T cell Response Against Chlamydia (TRAC) Study. 38
29563165 2018
144
Use of a Sentinel Lymph Node Biopsy Algorithm in a South African Population of Patients With Cervical Cancer and High Prevalence of Human Immunodeficiency Virus Infection. 38
30036220 2018
145
Uncommon cause of pelvic inflammatory disease leading to toxic shock syndrome. 38
30249728 2018
146
Molecular Diagnosis of Bacterial Vaginosis: an Update. 38
29769280 2018
147
'It Opened My Eyes'-examining the impact of a multifaceted chlamydia testing intervention on general practitioners using Normalization Process Theory. 38
29608672 2018
148
Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. 38
30201794 2018
149
Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. 38
29935395 2018
150
Relationships between female infertility and female genital infections and pelvic inflammatory disease: a population-based nested controlled study. 38
30110069 2018
151
Long-term physical health consequences of abortion in Taiwan, 2000 to 2013: A nationwide retrospective cohort study. 38
30075608 2018
152
LC-Q-TOF-MS based plasma metabolomic profile of subclinical pelvic inflammatory disease: A pilot study. 38
29709453 2018
153
HIV and Syphilis Screening Among Adolescents Diagnosed With Pelvic Inflammatory Disease. 38
30042114 2018
154
Racial/Ethnic Disparities in the Lifetime Risk of Chlamydia trachomatis Diagnosis and Adverse Reproductive Health Outcomes Among Women in King County, Washington. 38
29420716 2018
155
Serum procalcitonin levels together with clinical features and inflammatory markers in women with tubo-ovarian abscess for discriminating requirements for surgery for full recovery. 38
29523046 2018
156
Pneumoperitoneum caused by tubo-ovarian abscess in an elderly patient. 38
30093992 2018
157
Clinical experience with a novel anchored, frameless copper-releasing contraceptive device for intra-caesarean insertion. 38
30273057 2018
158
Specific Binding to Differentially Expressed Human Carcinoembryonic Antigen-Related Cell Adhesion Molecules Determines the Outcome of Neisseria gonorrhoeae Infections along the Female Reproductive Tract. 38
29760215 2018
159
Transcriptome Analysis of Neisseria gonorrhoeae during Natural Infection Reveals Differential Expression of Antibiotic Resistance Determinants between Men and Women. 38
29950382 2018
160
To 'douche' or not to 'douche': hygiene habits may have detrimental effects on vaginal microbiota. 38
29433363 2018
161
An integrative investigation of the therapeutic mechanism of Ainsliaea fragrans Champ. in cervicitis using liquid chromatography tandem mass spectrometry based on a rat plasma metabolomics strategy. 38
29729635 2018
162
The effect of antibiotic prophylaxis for acute pelvic inflammatory disease after hysterosalpingography: a retrospective cohort study. 38
29239678 2018
163
Spinal epidural abscess caused by Gardnerella vaginalis and Prevotella amnii. 38
30140147 2018
164
Prediction of recurrent ectopic pregnancy: A five-year follow-up cohort study. 38
29679814 2018
165
Obstructive Müllerian Anomalies in Menstruating Adolescent Girls: A Report of 22 Cases. 38
29030159 2018
166
Pyrexia of unknown origin: inferior vena cava agenesis. 38
29936445 2018
167
[Gynecological management and follow-up in women with cystic fibrosis]. 38
29958717 2018
168
Glycosylation-dependent galectin-receptor interactions promote Chlamydia trachomatis infection. 38
29891717 2018
169
Safety and efficacy of tigecycline in complicated and uncomplicated pelvic inflammatory disease. 38
29917214 2018
170
Pyosalpinx complicating chronic hydrosalpinx in a 50-year old virgo woman: a case report. 38
29890968 2018
171
Highlighting the clinical need for diagnosing Mycoplasma genitalium infection. 38
29431025 2018
172
Appraisal of clinical complications after 23,827 oocyte retrievals in a large assisted reproductive technology program. 38
29871795 2018
173
Use of the mtrR Gene for Rapid Molecular Diagnosis of Neisseria gonorrhoeae and Identification of the Reduction of Susceptibility to Antibiotics in Endocervical Swabs. 38
29589256 2018
174
Ureaplasma urealyticum: the Role as a Pathogen in Women's Health, a Systematic Review. 38
29959546 2018
175
A Silent Epidemic: The Prevalence, Incidence and Persistence of Mycoplasma genitalium Among Young, Asymptomatic High-Risk Women in the United States. 38
29342269 2018
176
Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections. 38
29483122 2018
177
Is intrauterine device a risk factor for failure of conservative management in patients with tubo-ovarian abscess? An observational retrospective study. 38
29478102 2018
178
Influence of Contraception Use on the Reproductive Health of Adolescents and Young Adults. 38
30046195 2018
179
Discovery of Blood Transcriptional Endotypes in Women with Pelvic Inflammatory Disease. 38
29531169 2018
180
Screening for Mullerian anomalies in patients with unilateral renal agenesis: Leveraging early detection to prevent complications. 38
29459133 2018
181
Severe Sepsis and Acute Myocardial Dysfunction in an Adolescent with Chlamydia Trachomatis Pelvic Inflammatory Disease: A Case Report. 38
29037929 2018
182
Pelvic inflammatory disease due to Streptococcus pneumoniae. 38
28807391 2018
183
Gonococcal and Chlamydial Cases of Pelvic Inflammatory Disease at 2 Canadian Sexually Transmitted Infection Clinics, 2004 to 2014: A Retrospective Cross-sectional Review. 38
29465704 2018
184
[Intrauterine device and pelvic inflammatory disease: Myth or reality?] 38
29627410 2018
185
Biological feasibility and importance of a gonorrhea vaccine for global public health. 38
29680200 2018
186
Detection of Chlamydia trachomatis in Pap Smear Samples from South Khorasan Province of Iran. 38
29334204 2018
187
Fitz-Hugh-Curtis syndrome associated with tuberculous salpingitis and peritonitis: a case presentation and review of literature. 38
29558895 2018
188
Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles. 38
29382248 2018
189
Ten years transmission of the new variant of Chlamydia trachomatis in Sweden: prevalence of infections and associated complications. 38
28724744 2018
190
Acupuncture for chronic pelvic inflammatory disease: A systematic review protocol. 38
29595670 2018
191
Acute pelvic inflammatory disease as a rare cause of acute small bowel obstruction. 38
29560794 2018
192
Sustained Simultaneous Delivery of Metronidazole and Doxycycline From Polycaprolactone Matrices Designed for Intravaginal Treatment of Pelvic Inflammatory Disease. 38
29100864 2018
193
Management and obstetric outcomes of 17 heterotopic interstitial pregnancies. 38
29587664 2018
194
Pelvic Pain in Adolescents. 38
30566977 2018
195
Urological dysfunction in young women: an inheritance of childhood? 38
29160004 2018
196
Identifying acute cervicitis in an era of less-frequent routine gynecologic examinations. 38
29369931 2018
197
How to differentiate acute pelvic inflammatory disease from acute appendicitis ? A decision tree based on CT findings. 38
28894927 2018
198
Predictive factors for emergent surgical intervention in patients with ovarian endometrioma hospitalized for pelvic inflammatory disease: A retrospective observational study. 38
29171117 2018
199
Risk of pelvic inflammatory disease after intrauterine insemination: a systematic review. 38
29287941 2018
200
Toll-like receptor variants and cervical Atopobium vaginae infection in women with pelvic inflammatory disease. 38
29286178 2018
201
2017 European guideline for the management of pelvic inflammatory disease. 38
29198181 2018
202
Intravaginal Administration of Interleukin 12 during Genital Gonococcal Infection in Mice Induces Immunity to Heterologous Strains of Neisseria gonorrhoeae. 38
29404418 2018
203
Pathogenesis of Neisseria gonorrhoeae and the Host Defense in Ascending Infections of Human Fallopian Tube. 38
30524442 2018
204
Gene Expression Signatures Can Aid Diagnosis of Sexually Transmitted Infection-Induced Endometritis in Women. 38
30294592 2018
205
Cost-effectiveness of microscopy of urethral smears for asymptomatic Mycoplasma genitalium urethritis in men in England. 38
28669322 2018
206
Hysterosalpingogram findings among subfertile women undergoing assisted reproductive technology. 38
30147380 2018
207
Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects. 38
29264970 2018
208
Pathogenesis of Neisseria gonorrhoeae in the female reproductive tract: neutrophilic host response, sustained infection, and clinical sequelae. 38
29016383 2018
209
Chlamydia trachomatis: Protective Adaptive Responses and Prospects for a Vaccine. 38
27033698 2018
210
PubMLST for Antigen Allele Mining to Inform Development of Gonorrhea Protein-Based Vaccines. 38
30581422 2018
211
Sliding-strip microfluidic device enables ELISA on paper. 38
28738231 2018
212
Risk factors for ectopic pregnancy in a population of Cameroonian women: A case-control study. 38
30540783 2018
213
Gynecological emergency ultrasound in daytime and at night: differences that cannot be ignored. 38
29950851 2018
214
Association between Prior Chlamydia trachomatis Infection and Ectopic Pregnancy at a Tertiary Care Hospital in South Western Uganda. 38
29686708 2018
215
Fitz-Hugh-Curtis Syndrome: A Diagnosis to Consider in a Woman with Right Upper Quadrant Abdominal Pain without Gallstones. 38
30756005 2018
216
Patient Satisfaction and Treatment Adherence for Urban Adolescents and Young Adults with Pelvic Inflammatory Disease. 38
29756068 2018
217
Adhesive Small Bowel Obstruction due to Pelvic Inflammatory Disease: A Case Report. 38
30787816 2018
218
Pelvic Inflammatory Disease: Possible Catches and Correct Management in Young Women. 38
30112235 2018
219
Trends in pelvic inflammatory disease emergency department visits, United States, 2006-2013. 38
29045851 2018
220
[Effect of Acupuncture on Inflammatory Cytokines in Patients with Acute Pelvic Inflammatory Disease]. 38
29383896 2018
221
Anti-Inflammatory Effect of Feiyangchangweiyan Capsule on Rat Pelvic Inflammatory Disease through JNK/NF-κB Pathway. 38
29681986 2018
222
Metabonomic study of the protective effect of Fukeqianjin formula on multi-pathogen induced pelvic inflammatory disease in rats. 38
30555525 2018
223
Pelvic inflammatory disease risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus non-NAATs in Denmark: A retrospective cohort. 38
29293503 2018
224
Relationship Status and Sexual Behaviors in Post-Pelvic Inflammatory Disease (PID) Affected Urban Young Women: A Sub-Study of a Randomized Controlled Trial. 38
30221216 2018
225
Impact of the Levonorgestrel-Releasing Intrauterine System on the Progression of Chlamydia trachomatis Infection to Pelvic Inflammatory Disease in a Baboon Model. 38
29253201 2018
226
Risk of Pelvic Inflammatory Disease in Relation to Chlamydia and Gonorrhea Testing, Repeat Testing, and Positivity: A Population-Based Cohort Study. 38
29136127 2018
227
A 41-Year-Old Patient with a Rare Cause of Severe Abdominal Sepsis Misdiagnosed as PID. 38
29850363 2018
228
Chlamydia trachomatis as the Cause of Infectious Infertility: Acute, Repetitive or Persistent Long-Term Infection? 38
27370345 2018
229
Diagnostic Hysterolaparoscopy for Evaluation of Infertility: Our Experience in a Tertiary Care Hospital. 38
29681711 2018
230
Pediatric Foley Catheter Placement After Operative Hysteroscopy Does Not Cause Ascending Infection. 38
28847756 2018
231
[Síndrome de Fitz-Hugh-Curtis en un paciente varón anciano. Caso y revisión de la literatura]. 38
30226491 2018
232
Pyosalpinges after hysterosalpingography in a patient with lower genital tract infection and managed by laparoscopic surgery in a resource low tertiary hospital case report and literature review. 38
29686882 2018
233
Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens. 38
29295593 2017
234
What Antibiotic Regimen Is Most Efficacious in Treating Pelvic Inflammatory Disease? 38
28822590 2017
235
Tubo-Ovarian Abscess in a Virginal Adolescent with Labial Agglutination Due to Lichen Sclerosus. 38
28522404 2017
236
Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model. 38
29170443 2017
237
Contraception Update: Intrauterine Devices. 38
29172412 2017
238
Does Active Oral Sex Contribute to Female Infertility? 38
29029270 2017
239
Early screening for Chlamydia trachomatis in young women for primary prevention of pelvic inflammatory disease (i-Predict): study protocol for a randomised controlled trial. 38
29132441 2017
240
A Population-Based Epidemiologic Study of Female Sexual Dysfunction Risk in Mainland China: Prevalence and Predictors. 38
29110805 2017
241
The global health impact of vaginal dysbiosis. 38
28257809 2017
242
The Effect of Vaccination Against Human Papillomavirus on Fecundability. 38
28881394 2017
243
A Single Dual-Function Enzyme Controls the Production of Inflammatory NOD Agonist Peptidoglycan Fragments by Neisseria gonorrhoeae. 38
29042497 2017
244
Chlamydia trachomatis: the Persistent Pathogen. 38
28835360 2017
245
Assessment of menstrual hygiene among reproductive age women in South-west Delhi. 38
29564253 2017
246
National Institute of Allergy and Infectious Diseases workshop report: "Chlamydia vaccines: The way forward". 38
29097007 2017
247
Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat. 38
28754299 2017
248
Frequency and genotypes of Chlamydia trachomatis in patients attending the obstetrics and gynecology clinics in Jalisco, Mexico and correlation with sociodemographic, behavioral, and biological factors. 38
28915869 2017
249
CT and MR Imaging of Gynecologic Emergencies. 38
28753380 2017
250
Cell-free production of a functional oligomeric form of a Chlamydia major outer-membrane protein (MOMP) for vaccine development. 38
28739800 2017
251
An incidental finding of chronic salpingitis complications: Tubo-uterine fistula. 38
28976128 2017
252
Curative effect of Jin'gangteng capsule combined with Kangfuxiaoyan suppository in the treatment of chronic pelvic inflammatory disease. 38
29105625 2017
253
Assessment of urinary cotinine levels in women with gynecological complaints at a tertiary care hospital: A pilot study. 38
28928322 2017
254
Prevalence and significance of Mycoplasma genitalium in women living with HIV in Denmark. 38
28882163 2017
255
Structural characterization of the NAP; the major adhesion complex of the human pathogen Mycoplasma genitalium. 38
28671286 2017
256
Provider and lay perspectives on intra-uterine contraception: a global review. 38
28950913 2017
257
Microbial infection, inflammation and epithelial ovarian cancer. 38
28789426 2017
258
Sexually transmitted infections: challenges ahead. 38
28701272 2017
259
Anti-inflammatory effect of Man-Pen-Fang, a Chinese herbal compound, on chronic pelvic inflammation in rats. 38
28652014 2017
260
Ectopic abdominal pregnancy due to uterine perforation after an attempt to terminate pregnancy: a case presentation. 38
28753590 2017
261
Imaging of Acute Pelvic Pain in Girls: Ovarian Torsion and Beyond☆. 38
28185689 2017
262
Mycoplasma genitalium: Accurate Diagnosis Is Necessary for Adequate Treatment. 38
28838072 2017
263
The Unique Microbiology and Molecular Pathogenesis of Mycoplasma genitalium. 38
28838077 2017
264
Mycoplasma genitalium in Women: Current Knowledge and Research Priorities for This Recently Emerged Pathogen. 38
28838078 2017
265
Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial. 38
28265816 2017
266
Mycoplasma/Ureaplasma infection in pregnancy: to screen or not to screen. 38
28099135 2017
267
Outcomes of Elective Outpatient Hysteroscopic Sterilization in Undocumented Women: A Retrospective Analysis. 38
28385588 2017
268
Barriers and myths that limit the use of intrauterine contraception in nulliparous women: a survey of Brazilian gynaecologists. 38
27780879 2017
269
Effect of cold water-induced stress on immune response, pathology and fertility in mice during Chlamydia muridarum genital infection. 38
28431099 2017
270
Developing a Public Health Response to Mycoplasma genitalium. 38
28838079 2017
271
The Immunopathogenesis of Mycoplasma genitalium Infections in Women: A Narrative Review. 38
28608793 2017
272
Bilateral recurrent pyosalpinx in a sexually inactive 12-year-old girl secondary to rare variant of Mullerian duct anomaly. 38
28647716 2017
273
Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. 38
28342087 2017
274
Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology. 38
28413133 2017
275
The Netherlands Chlamydia cohort study (NECCST) protocol to assess the risk of late complications following Chlamydia trachomatis infection in women. 38
28399813 2017
276
Socioeconomic status of parents and the occurrence of pelvic inflammatory disease among undergraduates attending Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria. 38
28762367 2017
277
Antibiotics Prophylaxis for Operative Hysteroscopy. 38
27470152 2017
278
Antibiotic therapy for pelvic inflammatory disease. 38
28436019 2017
279
Pelvic Inflammatory Disease in Virgin Women With Tubo-ovarian Abscess: A Single-Center Experience and Literature Review. 38
26260586 2017
280
[Advantages and evidences research on Chinese medicine for treatment of pelvic inflammatory disease]. 38
29071846 2017
281
Postpartum tubo-ovarian abscess, likely arising from pelvic inflammatory disease during pregnancy. 38
28408537 2017
282
Validity of self-reported history of Chlamydia trachomatis infection. 38
27988270 2017
283
[Guizhi Fuling capsule / pill treatment for chronic pelvic inflammatory disease:a systematic review of randomized clinical trials]. 38
29071853 2017
284
Comparative Assessment of Women's Reproductive Health in the Areas Bordering With the Aral Sea Region. 38
28507639 2017
285
Chinese medicine as complementary therapy for female infertility. 38
27484764 2017
286
Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas. 38
28432313 2017
287
Gender Differences in CDC Guideline Compliance for STIs in Emergency Departments. 38
28435489 2017
288
MRI in pelvic inflammatory disease: a pictorial review. 38
27933478 2017
289
Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. 38
27930941 2017
290
A Community Based Study on Pelvic Inflammatory Disease in Postmenopausal Females: Microbiological Spectrum and Socio-Demographic Correlates. 38
28511414 2017
291
Tubal Disease and Impersonators/Masqueraders. 38
28005596 2017
292
Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far? 38
27928678 2017
293
Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. 38
28084114 2017
294
Actinomyces-Related Tubo-Ovarian Abscess in a Poorly Controlled Type II Diabetic With a Copper Intrauterine Device. 38
28290977 2017
295
[Clinical analysis of pelvic abscess with endometriosis]. 38
28355687 2017
296
FDG PET/CT Pitfalls in Gynecologic and Genitourinary Oncologic Imaging. 38
28287942 2017
297
Epidemiology of ovarian cancer: a review. 38
28443200 2017
298
Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all? 38
27288417 2017
299
Reproductive outcomes of patients being hospitalised with pelvic inflammatory disease. 38
27750467 2017
300
MDCT of pelvic inflammatory disease: a review of the pathophysiology, gamut of imaging findings, and treatment. 38
27646971 2017
301
Pelvic inflammatory disease. 38
28098673 2017
302
Characteristics of pelvic inflammatory disease where no sexually transmitted infection is identified: a cross-sectional analysis of routinely collected sexual health clinic data. 38
27091727 2017
303
Should Female Partners of Men With Non-Gonococcal Urethritis, Negative for Chlamydia trachomatis and Mycoplasma genitalium, Be Informed and Treated? Clinical Outcomes From a Partner Study of Heterosexual Men With NGU. 38
28079749 2017
304
Comparing the Frequency of Endometritis in Unexplained Infertility and Anovulatory Infertility. 38
29285481 2017
305
Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. 38
28111145 2017
306
Clinical characteristics of genital chlamydia infection in pelvic inflammatory disease. 38
28086838 2017
307
Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England. 38
27678278 2017
308
Prevalence of Pelvic Inflammatory Disease in Sexually Experienced Women of Reproductive Age - United States, 2013-2014. 38
28125569 2017
309
Herlyn-Werner-Wunderlich Syndrome: Sonographic and Magnetic Resonance (MR) Imaging Findings of This Rare Urogenital Anomaly. 38
28469738 2017
310
Erroneously Suspected Ovarian Cancer in a 38-Year-Old Woman with Pelvic Inflammatory Disease and Chlamydia. 38
29391959 2017
311
Is Pelvic Inflammatory Disease a Risk Factor for Ovarian Cancer? 38
27672055 2017
312
Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. 38
27941069 2017
313
Comparison of Murine Cervicovaginal Infection by Chlamydial Strains: Identification of Extrusions Shed In vivo. 38
28217555 2017
314
Correlation of clinical and biological evidence - a dominant therapeutic element of succeeding in ectopic pregnancy. 38
28523313 2017
315
Analysis Of Two Years Cases Of Ectopic Pregnancy. 38
28712177 2017
316
Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis. 38
28199392 2017
317
Usefulness of Serum Procalcitonin Levels in Predicting Tubo-Ovarian Abscess in Patients with Acute Pelvic Inflammatory Disease. 38
27592364 2017
318
Anti-inflammatory Effects of the Natural Compounds Cortex Phellodendri and Humulus japonicus on Pelvic Inflammatory Disease in Mice. 38
28824307 2017
319
Whole-Exome Sequencing to Identify Novel Biological Pathways Associated With Infertility After Pelvic Inflammatory Disease. 38
27898568 2017
320
Mesenchymal Stem Cells in Restoration of Fertility at Experimental Pelvic Inflammatory Disease. 38
28928773 2017
321
The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. 38
28529540 2017
322
Current perspectives in the USA on the diagnosis and treatment of pelvic inflammatory disease in adolescents. 38
28721112 2017
323
Sexually transmitted diseases and infertility. 38
28007229 2017
324
Chlamydia trachomatis-induced Fitz-Hugh-Curtis syndrome: a case report. 38
28057084 2017
325
[Confusion caused by dietary supplement lithium orotate]. 38
28421576 2017
326
A review of intrauterine contraception in the Asia-Pacific region. 38
27570141 2017
327
Recurring Lower Abdominal Pain and Fever as Initial Presentation of Adult Onset Still's Disease in the Absence of Arthralgia and Other System Involvement. 38
30755951 2017
328
Human papillomavirus and Chlamydia trachomatis infection in gyneco-obstetric outpatients from a mexican hospital. 38
28303822 2017
329
Diversity of Cervical Microbiota in Asymptomatic Chlamydia trachomatis Genital Infection: A Pilot Study. 38
28770172 2017
330
Abdominal and pelvic actinomycosis due to longstanding intrauterine device: a slow and devastating infection. 38
28536687 2017
331
The safety of intrauterine devices among young women: a systematic review. 38
27771475 2017
332
Pelvic Inflammatory Disease: Diagnosis And Treatment In The Emergency Department. 38
27879197 2016
333
Gonorrhea Control, United States, 1972-2015, A Narrative Review. 38
27835623 2016
334
Pelvic inflammatory disease: diagnosis and treatment in the emergency department [digest]. 38
28745849 2016
335
The imaging findings of typical and atypical genital and gynecologic infections. 38
27251736 2016
336
Lytic transglycosylases LtgA and LtgD perform distinct roles in remodeling, recycling and releasing peptidoglycan in Neisseria gonorrhoeae. 38
27608412 2016
337
The safety of intrauterine contraception initiation among women with current asymptomatic cervical infections or at increased risk of sexually transmitted infections. 38
27263041 2016
338
Safety of intrauterine devices among women with HIV: a systematic review. 38
27343750 2016
339
Chlamydia trachomatis Is Resistant to Inclusion Ubiquitination and Associated Host Defense in Gamma Interferon-Primed Human Epithelial Cells. 38
27965446 2016
340
A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement. 38
27180886 2016
341
The Impact of Prescriptions on Sex Partner Treatment Using Expedited Partner Therapy for Chlamydia trachomatis Infection, New York City, 2014-2015. 38
27893595 2016
342
Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone. 38
27893679 2016
343
Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. 38
27809870 2016
344
Population attributable fraction of pelvic inflammatory disease associated with chlamydia and gonorrhoea: a cross-sectional analysis of Australian sexual health clinic data. 38
27091729 2016
345
The anti-inflammatory effect of Andrographis paniculata (Burm. f.) Nees on pelvic inflammatory disease in rats through down-regulation of the NF-κB pathway. 38
27887650 2016
346
Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study. 38
27549433 2016
347
Sensing the enemy, containing the threat: cell-autonomous immunity to Chlamydia trachomatis. 38
28201690 2016
348
The effect of contraceptive methods on reproductive tract infections risk: a cross-sectional study having a sample of 52,481 women. 38
27538571 2016
349
Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. 38
27881151 2016
350
High chlamydia and gonorrhoea repeat positivity in remote Aboriginal communities 2009-2011: longitudinal analysis of testing for re-infection at 3 months suggests the need for more frequent screening. 38
27764650 2016
351
Care-Seeking Behavior After Notification Among Young Women With Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease. 38
27507807 2016
352
2016 European guideline on Mycoplasma genitalium infections. 38
27505296 2016
353
Hysterolaparoscopy in the Evaluation and Management of Female Infertility. 38
27651649 2016
354
Intestinal obstruction associated with ovarian remnant in postmenopausal female. 38
28096643 2016
355
Anorectal and Pelvic Pain. 38
27712641 2016
356
The value of ultrasonographic tubo-ovarian abscess morphology in predicting whether patients will require surgical treatment. 38
27381446 2016
357
Comparison of diagnostic accuracy of PCR and BACTEC with Lowenstein-Jensen culture and histopathology in the diagnosis of female genital tuberculosis in three subsets of gynaecological conditions. 38
27184457 2016
358
Background review for the 2016 European guideline on Mycoplasma genitalium infections. 38
27605499 2016
359
Chlamydia trachomatis Genital Infections. 38
28357377 2016
360
[Intractable Myasthenia Gravis Accompanied with Thymoma;Report of a Case]. 38
27586323 2016
361
Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. 38
27289389 2016
362
Gonorrhea - an evolving disease of the new millennium. 38
28357376 2016
363
Increased Gonorrhea Cases - Utah, 2009-2014. 38
27583786 2016
364
Pelvic Inflammatory Disease: Multimodality Imaging Approach with Clinical-Pathologic Correlation. 38
27618331 2016
365
Identification of novel microbes associated with pelvic inflammatory disease and infertility. 38
26825087 2016
366
Screening for genital chlamydia infection. 38
27623210 2016
367
Invited Commentary on "Pelvic Inflammatory Disease," with Response from Dr Revzin and Colleagues. 38
27618332 2016
368
Establishment of hydrochloric acid/lipopolysaccharide-induced pelvic inflammatory disease model. 38
26726020 2016
369
Chlamydia trachomatis Genital Tract Infections: When Host Immune Response and the Microbiome Collide. 38
27320172 2016
370
Pregnancy after fertility-sparing surgery for borderline ovarian tumors. 38
27352738 2016
371
The role of serological testing for Chlamydia trachomatis in differential diagnosis of pelvic pain. 38
27660878 2016
372
Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan. 38
27452428 2016
373
Pelvic inflammatory disease. 38
27107781 2016
374
Proportion of Pelvic Inflammatory Disease Cases Caused by Chlamydia trachomatis: Consistent Picture From Different Methods. 38
27260786 2016
375
Updated French guidelines for diagnosis and management of pelvic inflammatory disease. 38
27170602 2016
376
Recruitment of Minority Adolescents and Young Adults into Randomised Clinical Trials: Testing the Design of the Technology Enhanced Community Health Nursing (TECH-N) Pelvic Inflammatory Disease Trial. 38
27617108 2016
377
Lactobacillus crispatus strain SJ-3C-US induces human dendritic cells (DCs) maturation and confers an anti-inflammatory phenotype to DCs. 38
27245496 2016
378
An outbreak of high-lev